Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
about
Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasiaVIN usual type-from the past to the futureDiscussing the diagnosis of HPV-OSCC: common questions and answersAnal dysplasia in HIV-infected women: a commentary on the field.Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study.Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trialWhat do women with gynecologic cancer know about HPV and their individual disease? A pilot study.Is administration of the HPV vaccine during pregnancy feasible in the future?Anal cancer treatment: current status and future perspectives.Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact.Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasiaSystematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure.Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men.Human papillomavirus vaccination: current indications and future directionsLaser capture microdissection as a tool to evaluate human papillomavirus genotyping and methylation as biomarkers of persistence and progression of anal lesionsThe incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review.Long-Term Outcomes of Adding HPV Vaccine to the Anal Intraepithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men.HPV prophylactic vaccination in males improves the clearance of semen infection.The time has come to make cervical cancer prevention an essential part of comprehensive sexual and reproductive health services for HIV-positive women in low-income countries"Saving lives": Adapting and adopting Human Papilloma Virus (HPV) vaccination in AustriaVaccination against HPV-Associated Neoplasias: Recommendations from the Current S3 Guideline of the HPV Management Forum of the Paul-Ehrlich Society - AWMF Guidelines, Registry No. 082-002 (short version), valid until Dec. 31st, 2018Sexual and reproductive health and human rights of women living with HIV.Should male circumcision be advocated for genital cancer prevention?Answering human papillomavirus vaccine concerns; a matter of science and time.Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trialsEffectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia.Early infant male circumcision: Systematic review, risk-benefit analysis, and progress in policy.The role of Human Papilloma Virus (HPV) vaccination in the prevention of anal cancer in individuals with Human Immunodeficiency Virus-1 (HIV-1) infectionHuman papillomavirus vaccines: where do they fit in HIV-infected individuals?Understanding and learning from the success of prophylactic human papillomavirus vaccines.Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients.Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme.Prevention, identification and treatment of vulvar squamous (pre)malignancies: a review focusing on quality of care.Human papillomavirus vaccination: where are we now?Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.Site of infections associated with human papillomavirus.Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs.Cervical cancer: A comprehensive approach towards extermination.Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.Treatment outcomes of recurrent respiratory papillomatosis : Retrospective analysis of juvenile and adult cases.
P2860
Q24186582-CB03756F-E3BB-4EC7-A36A-59E740C38256Q26865303-83A44A91-2BF8-4782-91A6-2CB6D24C93DAQ27000693-69BE2F75-E8D8-4356-B0EF-479365448C1AQ30252055-82E38F49-E365-487F-8E80-C1DA712ABDF2Q30667372-019640F0-038F-43EC-BEF5-138257AAF2FCQ33626255-BAEECB49-AEC3-4AE0-93A2-7A53345D912DQ33716245-2AFA45BC-A348-475B-9429-B8B64321010DQ33920755-A375EE49-5DB3-4BB3-A839-EACCDFF4BC1EQ34465769-D52FBF6E-256C-4FA6-8EB9-A1AAF9A248DAQ34493286-43C3F111-E062-4D49-81D0-860AFC580446Q34625933-2BC8FDD5-166E-4710-8A52-5D12CFFF13DFQ35111092-F5866DF9-FB3B-4960-9F90-975F14011F29Q35143152-35232123-ABFE-4162-8717-E1A3C709F266Q35558593-0EB904E4-FA22-4D0B-AC75-9A6ADDCEA37FQ35756579-99265CF3-F814-4E89-88F7-EAF0CCF45D34Q35984769-43895EE5-AB41-4E7B-8D1E-2E7D8756230BQ36187651-30FEE252-E043-4939-A067-3846C63C47F6Q36252874-319750AE-931B-4B51-939B-8021674AE657Q36353824-8D18C2A2-3993-4303-AE61-3F494353E307Q36681143-B84DF1ED-1052-4A93-87E4-B3197167C216Q36743080-1341031F-5795-422A-84DD-4E7D2142E9F9Q36744865-ADD07F29-559C-4B56-9C4F-8C9C447D85CEQ36890800-1D4EF02C-2AFA-4E41-BC8F-378FEE1282FAQ36952972-E1AF9092-BAB5-4E14-BDE8-E1125A03423BQ37425284-447CBFB2-A476-4A48-8064-15F7C092AA66Q37616577-34DB0692-4443-421E-AA47-B91D0F3E6927Q37630319-1671B479-869D-429E-8BDB-1D7483EC82B4Q37668390-D6FC9663-1F08-40CE-8AC4-96FE2B60A0D8Q38022478-7E0A6959-D30E-4051-95A4-87C7BB91D4CAQ38041983-A5E74813-4007-4CC8-BA0C-FBE429DA9875Q38078770-36A37ABE-8F9E-4623-AC14-E22878E0E940Q38110696-7763B7FF-CD2B-4237-B326-7B220AF78A0EQ38123205-943CED32-A87A-4FF2-B4EB-52D0516F72FFQ38218612-222C936E-A244-4999-A469-0230D9DBDDECQ38229304-794849A6-F1D2-4164-A4DA-7F9FBE11143AQ38253253-5CE7C13C-9637-4079-B152-FE7CA266AA78Q38255277-B89B501B-9DDB-4297-B58D-7789FEC4BB25Q38748682-01762C34-528A-4457-86A4-EB356AB3773EQ38906082-40F301F9-A87F-4842-9E5A-26FDA79A3A3FQ40070800-F885682A-ABC2-479B-9CFE-7D7DBB2E5EDA
P2860
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Effect of the human papillomav ...... pooled analysis of trial data.
@ast
Effect of the human papillomav ...... pooled analysis of trial data.
@en
Effect of the human papillomavirus
@nl
type
label
Effect of the human papillomav ...... pooled analysis of trial data.
@ast
Effect of the human papillomav ...... pooled analysis of trial data.
@en
Effect of the human papillomavirus
@nl
prefLabel
Effect of the human papillomav ...... pooled analysis of trial data.
@ast
Effect of the human papillomav ...... pooled analysis of trial data.
@en
Effect of the human papillomavirus
@nl
P2093
P2860
P356
P1433
P1476
Effect of the human papillomav ...... pooled analysis of trial data.
@en
P2093
Daron G Ferris
Elmar A Joura
FUTURE I and II Study Group
Gonzalo Perez
Heather L Sings
Kevin A Ault
Margaret K James
Richard M Haupt
Suzanne M Garland
Warner K Huh
P2860
P356
10.1136/BMJ.E1401
P407
P577
2012-03-27T00:00:00Z